Addex Therapeutics furnishes press release via 6-K on Oct 29, 2025

Rhea-AI Filing Summary

Addex Therapeutics (ADXN) furnished a Form 6-K noting it issued a press release on October 29, 2025, attached as Exhibit 99.1 and incorporated by reference.

The press release is deemed part of Addex’s registration statements on Form F-3 (No. 333-255089) and Form S-8 (Nos. 333-255124 and 333-272515) from the filing date, unless later superseded.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-39179

Addex Therapeutics Ltd
(Translation of registrant's name into English)

Chemin des Mines 9,
CH-1202 Geneva,
Switzerland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

On October 29, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated October 29, 2025

INCORPORATION BY REFERENCE

Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Addex Therapeutics Ltd
		(Registrant)
Date: October 29, 2025		/s/ Tim Dyer
		Tim Dyer
		Chief Executive Officer

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press release dated October 29, 2025

FAQ

What did Addex Therapeutics (ADXN) file?

Addex furnished a Form 6-K reporting that it issued a press release on October 29, 2025.

What is included in the Form 6-K for ADXN?

The filing includes Exhibit 99.1, a press release dated October 29, 2025.

Which registration statements incorporate Exhibit 99.1 by reference for ADXN?

It is incorporated into Form F-3 (No. 333-255089) and Form S-8 (Nos. 333-255124 and 333-272515).

Does Addex file annual reports on Form 20-F or 40-F?

Addex indicates it files annual reports on Form 20-F.

What is the exhibit number and date in this ADXN filing?

The exhibit is Exhibit 99.1, a press release dated October 29, 2025.

Where is Addex Therapeutics’ principal executive office?

The address is Chemin des Mines 9, CH-1202 Geneva, Switzerland.